Home > Rheumatology > ACR 2020 > Spondyloarthritis – The Beat Goes On > Signs of benefit for T2T in axial spondyloarthritis

Signs of benefit for T2T in axial spondyloarthritis


Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22

Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/template-parts/content-structured.php on line 22
Conference
ACR 2020
Trial
Cohort study, TICOSPA
Although a treat-to-target strategy for managing patients with axial spondyloarthritis failed to meet its primary efficacy endpoint, there were several signs of benefit in the secondary outcomes compared with standard-of-care in the TICOSPA trial. The treat-to-target (T2T) management strategy is already adopted in rheumatoid arthritis (RA) patients and also recommended for axial spondylarthritis (axSpA), but no study has evaluated its benefit. The TICOSPA study (NCT03043846) aimed to assess whether patients with axSpA benefit from this approach [1]. The trial was performed at 10 French centres and 4 centres each in Belgium and the Netherlands. Included patients had an Ankylosing Spondylitis Disease Activity Score (ASDAS) >2.1 and had not yet received a biologic. Patients (n=160) were randomised 1:1 to either T2T or standard-of-care. Patients in the T2T group att...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on